File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1158/1078-0432.CCR-11-2555
- Scopus: eid_2-s2.0-84865740846
- PMID: 22753588
- WOS: WOS:000309964500005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Worth adapting? Revisiting the usefulness of outcome-adaptive randomization
Title | Worth adapting? Revisiting the usefulness of outcome-adaptive randomization |
---|---|
Authors | |
Issue Date | 2012 |
Publisher | American Association for Cancer Research. The Journal's web site is located at http://clincancerres.aacrjournals.org/ |
Citation | Clinical Cancer Research, 2012, v. 18 n. 17, p. 4498-4507 How to Cite? |
Abstract | Outcome-adaptive randomization allocates more patients to the better treatments as the information accumulates in the trial. Is it worth it to apply outcome-adaptive randomization in clinical trials? Different views permeate the medical and statistical communities. We provide additional insights to the question by conducting extensive simulation studies. Trials are designed to maintain the type I error rate, achieve a specified power, and provide better treatment to patients. Generally speaking, equal randomization requires a smaller sample size and yields a smaller number of nonresponders than adaptive randomization by controlling type I and type II errors. Conversely, adaptive randomization produces a higher overall response rate than equal randomization with or without expanding the trial to the same maximum sample size. When there are substantial treatment differences, adaptive randomization can yield a higher overall response rate as well as a lower average sample size and a smaller number of nonresponders. Similar results are found for the survival endpoint. The differences between adaptive randomization and equal randomization quickly diminish with early stopping of a trial due to efficacy or futility. In summary, equal randomization maintains balanced allocation throughout the trial and reaches the specified statistical power with a smaller number of patients in the trial. If the trial's results are positive, equal randomization may lead to early approval of the treatment. Adaptive randomization focuses on treating patients best in the trial. Adaptive randomization may be preferred when the difference in efficacy between treatments is large or when the number of patients available is limited. ©2012 AACR. |
Persistent Identifier | http://hdl.handle.net/10722/172509 |
ISSN | 2023 Impact Factor: 10.0 2023 SCImago Journal Rankings: 4.623 |
PubMed Central ID | |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, JJ | en_US |
dc.contributor.author | Chen, N | en_US |
dc.contributor.author | Yin, G | en_US |
dc.date.accessioned | 2012-10-30T06:22:51Z | - |
dc.date.available | 2012-10-30T06:22:51Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Clinical Cancer Research, 2012, v. 18 n. 17, p. 4498-4507 | en_US |
dc.identifier.issn | 1078-0432 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/172509 | - |
dc.description.abstract | Outcome-adaptive randomization allocates more patients to the better treatments as the information accumulates in the trial. Is it worth it to apply outcome-adaptive randomization in clinical trials? Different views permeate the medical and statistical communities. We provide additional insights to the question by conducting extensive simulation studies. Trials are designed to maintain the type I error rate, achieve a specified power, and provide better treatment to patients. Generally speaking, equal randomization requires a smaller sample size and yields a smaller number of nonresponders than adaptive randomization by controlling type I and type II errors. Conversely, adaptive randomization produces a higher overall response rate than equal randomization with or without expanding the trial to the same maximum sample size. When there are substantial treatment differences, adaptive randomization can yield a higher overall response rate as well as a lower average sample size and a smaller number of nonresponders. Similar results are found for the survival endpoint. The differences between adaptive randomization and equal randomization quickly diminish with early stopping of a trial due to efficacy or futility. In summary, equal randomization maintains balanced allocation throughout the trial and reaches the specified statistical power with a smaller number of patients in the trial. If the trial's results are positive, equal randomization may lead to early approval of the treatment. Adaptive randomization focuses on treating patients best in the trial. Adaptive randomization may be preferred when the difference in efficacy between treatments is large or when the number of patients available is limited. ©2012 AACR. | en_US |
dc.language | eng | en_US |
dc.publisher | American Association for Cancer Research. The Journal's web site is located at http://clincancerres.aacrjournals.org/ | - |
dc.relation.ispartof | Clinical Cancer Research | en_US |
dc.title | Worth adapting? Revisiting the usefulness of outcome-adaptive randomization | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yin, G: gyin@hku.hk | en_US |
dc.identifier.authority | Yin, G=rp00831 | en_US |
dc.description.nature | link_to_OA_fulltext | en_US |
dc.identifier.doi | 10.1158/1078-0432.CCR-11-2555 | en_US |
dc.identifier.pmid | 22753588 | - |
dc.identifier.pmcid | PMC3495976 | - |
dc.identifier.scopus | eid_2-s2.0-84865740846 | en_US |
dc.identifier.hkuros | 223929 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84865740846&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.issue | 17 | en_US |
dc.identifier.spage | 4498 | en_US |
dc.identifier.epage | 4507 | en_US |
dc.identifier.isi | WOS:000309964500005 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Lee, JJ=7601452666 | en_US |
dc.identifier.scopusauthorid | Chen, N=54882570100 | en_US |
dc.identifier.scopusauthorid | Yin, G=8725807500 | en_US |
dc.identifier.issnl | 1078-0432 | - |